Business Wire

causaLens launches the first causal AI platform

22.9.2020 16:00:00 EEST | Business Wire | Press release

Share

causaLens , a deep-tech company predicting and optimising the global economy, has released the World’s first causal Artificial Intelligence (causal AI) enterprise platform. Businesses no longer have to rely on curve-fitting machine learning platforms unable to handle the complexity of today's world. They are invited to join the real AI revolution with a platform that understands cause and effect.

The causaLens platform defines a new category of machine intelligence. Its next generation AI engine harnesses an understanding of cause and effect relationships to directly optimise business KPIs.

“Businesses investing in the current form of machine learning (ML), including AutoML, have just been paying to automate a process that fits curves to data without an understanding of the real world. They are effectively driving forward by looking in the rear-view mirror,” explains causaLens CEO Darko Matovski. “Our platform takes a radically different approach. Causal AI teaches machines to understand cause and effect, a necessary step to developing true AI. This allows our platform to autonomously operate at a new level of abstraction that explains to businesses what actions they need to take to achieve their objectives.”

causaLens has a track record of breaking new ground, having pioneered automated machine learning (AutoML) for time series data. The causal AI platform retains the advantages of comprehensive automation, allowing thousands of data sets to be cleaned, sorted and monitored at the same time. However, it combines it with causal models and insights that are truly explainable - traditionally the sole province of domain experts. Unique human knowledge is harnessed through intuitive interfaces for human-machine partnerships.

Since its inception in 2017, causaLens has worked with a range of corporates across multiple industries. Customers include some of the world’s largest Asset Managers, Hedge Funds, Tier-1 Investment Banks, Transportation and Logistics companies, and Energy and Commodity traders.

Masami Johnstone, Head of Information Services at CLS, whose products help clients navigate the changing Foreign Exchange marketplace, said: "The causaLens platform has enabled us to discover additional value in our data. Their causal AI technology autonomously finds valuable signals in huge datasets and has helped us to understand relationships between our data and other datasets.”

Today’s world is changing faster than ever before. Current state of the art ML barely scratches the surface of what machines can do. Causal AI is the next huge step forward.

Demonstrations of the product can be requested via causaLens.com.

causaLens

causaLens is pioneering Causal AI, a new category of intelligent machines that understand cause and effect - a major step towards true AI. Its enterprise platform is used to transform leading businesses in Finance, IoT, Energy, Telecommunications and others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Darko Matovski,
CEO and co-founder
E: darko@causalens.com
www.causaLens.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye